Neuland Laboratories Limited reported a stellar financial performance for the fiscal year ending March 31, 2026. The company achieved a consolidated annual revenue of ₹2,02,298.54 lakhs and a profit after tax of ₹36,399.84 lakhs. Additionally, the company announced a significant capacity expansion of 120.5 KL at its Unit 1 facility in Telangana, requiring an investment of ₹143.4 crores to meet growing market demand, alongside a final dividend recommendation of ₹34 per share.
Financial Performance Highlights
Neuland Laboratories Limited concluded the financial year ending March 31, 2026, with strong growth across its operations. Consolidated revenue from operations for the year reached ₹2,02,298.54 lakhs, compared to ₹1,47,683.73 lakhs in the previous year. The consolidated profit after tax for the year stood at ₹36,399.84 lakhs, reflecting a solid upward trajectory. For the fourth quarter alone (ending March 31, 2026), the company reported a quarterly revenue of ₹77,625.03 lakhs with a net profit of ₹21,267.26 lakhs.
Strategic Capacity Expansion
To address the growing global demand for its products, the Board has approved a capacity enhancement at its Unit 1 facility located in Bonthapally Village, Telangana. The project will add 120.5 KL to the existing capacity of 256 KL. With an investment of ₹143.4 crores (inclusive of GST), this initiative will be financed through internal accruals and borrowings and is expected to be completed within 12 to 18 months.
Dividend and Leadership Updates
Recognizing the company’s strong financial health, the Board of Directors has recommended a final dividend of ₹34 per equity share (representing 340% of the face value of ₹10) for the financial year 2025-26. The dividend will be subject to the approval of shareholders at the 42nd Annual General Meeting (AGM), scheduled for August 4, 2026, with the record date for entitlement set for July 24, 2026.
Furthermore, the company has strengthened its leadership team with the appointment of Dr. Mauricio Futran as an Additional Director, effective May 12, 2026. Dr. Futran brings over 40 years of extensive expertise in chemical engineering, process development, and manufacturing excellence from his tenure at global pharmaceutical leaders.
Source: BSE
